Advisory committee named to advance Boston Children’s SMART Platforms

Laura Pedulli | | Health Exec | Precision Medicine

A project at Boston Children’s Hospital (BCH) that is seeking to develop technology for an app-driven health information economy now has an advisory committee to advance its strategy, technical approach and business development.

BCH’s SMART (Substitutable Medical Apps & Reusable Technology) Platforms project aims to provide a flexible information infrastructure to facilitate innovation in wellness, healthcare and public health. This interface is expected to create a broad market for apps developers and a wide selection of apps for users of health IT, according to a hospital release.

The advisory committee includes the following representatives from the private, nonprofit and government sectors:

  • The Advisory Board Company
  • AARP
  • BMJ
  • Canadian Institutes of Health Research
  • Centers for Medicare and Medicaid Services
  • England National Health Service
  • Hospital Corporation of America
  • Eli Lilly and Company
  • MyHealthBook
  • Polyglot Systems
  • Surescripts

Harvard Medical School received funding to research and develop SMART platform in 2010 from the Office of the National Coordinator for Health IT as part of the Strategic Healthcare IT Advanced Research Projects program.

Also, the Patient-Centered Outcomes Research Institute recently awarded Harvard Medical School and BCH a $7 million grant to build a 10-site clinical research network called "Scalable Collaborative Infrastructure for a Learning Healthcare System," which will rely on SMART apps. 

For more information, go here.

 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.